Leslie L Sharp

US Patent:

20120237498, Sep 20, 2012

Filed:

Sep 9, 2011

Appl. No.:

13/228532

Inventors:

Bianca AHRENS - Munchen, DE
Sangita M. BAXI - San Diego CA, US
Timothy Scott FISHER - San Diego CA, US
Richard Michael JEROME - East Hampstead NH, US
Kathrin LADETZKI-BAEHS - Planegg, DE
Theodore OLIPHANT - Galesburg MI, US
Leslie Lynne SHARP - San Diego CA, US
Michael TESAR - Augsberg, DE
Libbey Anne YATES - Dardenne Prairie MO, US
Moritz ZULLEY - Munchen, DE

Assignee:

PFIZER INC - New York NY

International Classification:

A61K 39/395
C07K 16/00

US Classification:

4241301, 5303871

Abstract:

The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

US Patent:

20130078240, Mar 28, 2013

Filed:

Nov 14, 2012

Appl. No.:

13/676288

Inventors:

Pfizer Inc - New York NY, US
Sangita M. BAXI - San Diego CA, US
Timothy Scott FISHER - San Diego CA, US
Richard Michael JEROME - East Hampstead NH, US
Kathrin LADETZKI-BAEHS - Planegg, DE
Theodore OLIPHANT - Galesburg MI, US
Leslie Lynne SHARP - San Diego CA, US
Michael TESAR - Augsberg, DE
Libbey Anne YATES - Dardenne Prairie MO, US
Moritz ZULLEY - Munchen, DE

Assignee:

PFIZER INC - New York NY

International Classification:

C07K 16/28
A61K 45/06
A61K 39/395

US Classification:

4241331, 5303879, 4241391

Abstract:

The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

US Patent:

20230025706, Jan 26, 2023

Filed:

Aug 22, 2022

Appl. No.:

17/893052

Inventors:

- Phoenix AZ, US
- Scottsdale AZ, US
Nancy VILLA - Tempe AZ, US
Lino TORRES-DOMINGUEZ - Tempe AZ, US
Lina FRANCO ACHURY - Tempe AZ, US
Leslie Lynne SHARP - Rancho Santa Fe CA, US

International Classification:

C07K 14/005
A61K 39/275
A61P 35/04
A61K 45/06
C07K 14/54
C07K 14/525
C12N 7/00
A61K 39/00

Abstract:

Disclosed herein, in certain embodiments, are recombinant myxoma viruses (MYXVs) and nucleic acid constructs encoding the recombinant MYXVs. In some embodiments, the MYXVs are engineered to inactivate or attenuate an activity or expression level of an M153 protein. In some embodiments, the MYXVs are engineered to express one or more transgenes such as a tumor necrosis factor (TNF), interleukin-12 (IL-12), or decorin. Also disclosed herein, in certain embodiments, are methods of using the MYXVs. Some embodiments include providing a MYXV as described herein to a subject in need thereof.

US Patent:

20210324014, Oct 21, 2021

Filed:

Jun 24, 2021

Appl. No.:

17/357624

Inventors:

- Scottsdale AZ, US
- Phoenix AZ, US
Nancy VILLA - Tempe AZ, US
Lino TORRES-DOMINGUEZ - Tempe AZ, US
Lina FRANCO ACHURY - Tempe AZ, US
Leslie Lynne SHARP - Rancho Santa Fe CA, US

International Classification:

C07K 14/005
C07K 14/525
C07K 14/54
A61P 35/04
A61K 45/06
A61K 39/275
C12N 7/00

Abstract:

Disclosed herein, in certain embodiments, are recombinant myxoma viruses (MYXVs) and nucleic acid constructs encoding the recombinant MYXVs. In some embodiments, the MYXVs are engineered to inactivate or attenuate an activity or expression level of an M153 protein. In some embodiments, the MYXVs are engineered to express one or more transgenes such as a tumor necrosis factor (TNF), interleukin-12 (IL-12), or decorin. Also disclosed herein, in certain embodiments, are methods of using the MYXVs. Some embodiments include providing a MYXV as described herein to a subject in need thereof.

US Patent:

20210061864, Mar 4, 2021

Filed:

Sep 2, 2020

Appl. No.:

17/010711

Inventors:

- Scottsdale AZ, US
- Phoenix AZ, US
Nancy VILLA - Tempe AZ, US
Lino TORRES-DOMINGUEZ - Tempe AZ, US
Lina FRANCO ACHURY - Tempe AZ, US
Leslie Lynne SHARP - Rancho Santa Fe CA, US

International Classification:

C07K 14/005
C12N 7/00
C07K 14/525
C07K 14/54
A61P 35/04
A61K 45/06
A61K 39/275

Abstract:

Disclosed herein, in certain embodiments, are recombinant myxoma viruses (MYXVs) and nucleic acid constructs encoding the recombinant MYXVs. In some embodiments, the MYXVs are engineered to inactivate or attenuate an activity or expression level of an M153 protein. In some embodiments, the MYXVs are engineered to express one or more transgenes such as a tumor necrosis factor (TNF), interleukin-12 (IL-12), or decorin. Also disclosed herein, in certain embodiments, are methods of using the MYXVs. Some embodiments include providing a MYXV as described herein to a subject in need thereof.

US Patent:

20180194851, Jul 12, 2018

Filed:

Mar 6, 2018

Appl. No.:

15/913117

Inventors:

- New York NY, US
Sangita M. BAXI - San Diego CA, US
Timothy Scott FISHER - San Diego CA, US
Richard Michael JEROME - East Hampstead NH, US
Kathrin LADETZKI-BAEHS - Planegg, DE
Theodore Lawrence OLIPHANT - Galesburg MI, US
Leslie Lynne SHARP - San Diego CA, US
Michael TESAR - Augsberg, DE
Libbey Anne YATES - Dardenne Prairie MI, US
Moritz ZULLEY - Munchen, DE

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07K 16/28
C12N 15/62
A61K 38/02
C12N 5/07
A61K 39/395
A61K 45/06
C07K 16/30
A61K 39/00

Abstract:

The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

US Patent:

20160369000, Dec 22, 2016

Filed:

Sep 6, 2016

Appl. No.:

15/257715

Inventors:

- New York NY, US
Sangita M. Baxi - San Diego CA, US
Timothy Scott Fisher - San Diego CA, US
Richard Michael Jerome - East Hampstead NH, US
Kathrin Ladetzki-Baehs - Planegg, DE
Theodore Lawrence Oliphant - Galesburg MI, US
Leslie Lynne Sharp - San Diego CA, US
Michael Tesar - Augsberg, DE
Libbey Anne Yates - Dardenne Prairie MI, US
Moritz Zulley - Munchen, DE

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07K 16/28

Abstract:

The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

US Patent:

20140377255, Dec 25, 2014

Filed:

May 13, 2014

Appl. No.:

14/276351

Inventors:

- New York NY, US
Sangita M. Baxi - San Diego CA, US
Timothy Scott Fisher - San Diego CA, US
Richard Michael Jerome - East Hampstead NH, US
Kathrin Ladetzki-Baehs - Planegg, DE
Theodore Oliphant - Galesburg MI, US
Leslie Lynne Sharp - San Diego CA, US
Michael Tesar - Augsberg, DE
Libbey Anne Yates - Dardenne Prairie MO, US
Moritz Zulley - Munchen, DE

Assignee:

PFIZER INC - New York NY

International Classification:

A61K 39/395
C07K 16/30

US Classification:

4241331, 5303873, 536 2353, 4353201, 435 696, 435328, 43525233, 43525231, 4352523, 43525234, 43525235, 4352542

Abstract:

The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.